Scarica l'app Stockscreener
9.57
1.06%
0.10
Dopo l'orario di chiusura:
9.57
Precedente Chiudi:
$9.47
Aprire:
$9.53
Volume 24 ore:
97,481
Relative Volume:
0.42
Capitalizzazione di mercato:
$3.24B
Reddito:
$804.63M
Utile/perdita netta:
$-7.13M
Rapporto P/E:
-453.55
EPS:
-0.0211
Flusso di cassa netto:
$-73.42M
1 W Prestazione:
-5.90%
1M Prestazione:
-9.38%
6M Prestazione:
-1.85%
1 anno Prestazione:
-42.35%
Intervallo 1D:
$9.50
$9.63
Intervallo di 1 settimana:
$9.46
$10.28
Portata 52W:
$6.28
$18.49
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Nome
Telix Pharmaceuticals Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare TLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
9.57 | 3.21B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-05 | Iniziato | Wedbush | Outperform |
| 2024-11-15 | Iniziato | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Borsa (TLX) Ultime notizie
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing - GlobeNewswire Inc.
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Sahm
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
TLX101-Px (Pixlumi®) MAA Accepted in Europe - Sahm
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
Telix (NASDAQ: TLX) refinances with US$600M 2031 convertible bonds - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
Telix Strengthens Board with Additional Director Appointments - Sahm
Telix Pharmaceuticals (NASDAQ: TLX) expands board with two new NEDs - Stock Titan
Telix Appoints David Gill as Non-Executive Director - Sahm
[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3.63M indirect shares - Stock Titan
Telix (TLX) COO reports ordinary shares, ADRs and option-like awards - Stock Titan
Telix Pharmaceuticals (TLX) files 20-F/A to correct exhibit links - Stock Titan
Telix Pharmaceuticals (TLX) director reports 595,000 shares held via Forellan - Stock Titan
Telix (TLX) CEO details ADRs, options and large indirect stake - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3,719 Ordinary Shares - Stock Titan
Telix Pharmaceuticals Limited (TLX) Stock Price, News, Quote & History - Yahoo Finance
Telix (NASDAQ: TLX) resubmits FDA NDA for Pixclara brain cancer imaging agent - Stock Titan
Latest TLX NewsTelix to Showcase Urology Pipeline at Upcomi... - Stock Titan
Stock of the day: Telix Pharmaceuticals - ig.com
Telix Signals Upcoming Escrow Share Release - Colitco
How new prostate scans could change care: Telix hosts doctor Q&A - Stock Titan
Global prostate scan registry taps AI to predict survival - Stock Titan
Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz
Telix leaders to speak at Oppenheimer and TD Cowen, sessions streamed live - Stock Titan
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Telix submits European marketing application for brain cancer imaging agent By Investing.com - Investing.com India
Telix Pharmaceuticals stock rises after European regulatory submission By Investing.com - Investing.com India
Sea Limited Sponsored ADR (SE) Rises Higher Than Market: Key Facts - Yahoo Finance
Telix Pharmaceuticals Ltd Adr Azioni (TLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Telix Pharmaceuticals Ltd Adr Azioni (TLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Behrenbruch Christian | MD & Group CEO |
Apr 29 '26 |
Buy |
14.87 |
33,435 |
497,178 |
20,742,935 |
| Smith Darren Charlton | Group Chief Financial Officer |
Mar 29 '26 |
Option Exercise |
0.00 |
1,111 |
0 |
11,921 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):